Detalhe da pesquisa
1.
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
Proc Natl Acad Sci U S A
; 110(19): 7922-7, 2013 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23620515
2.
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Nat Chem Biol
; 8(11): 890-6, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23023262
3.
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Mol Cancer Ther
; 16(11): 2586-2597, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28835384
4.
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
PLoS One
; 12(1): e0170539, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28085948
5.
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
PLoS One
; 11(7): e0158888, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27391784
6.
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.
ACS Med Chem Lett
; 6(5): 491-5, 2015 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26005520
7.
Reaction coupling between wild-type and disease-associated mutant EZH2.
ACS Chem Biol
; 9(11): 2459-64, 2014 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25154026
8.
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
PLoS One
; 9(12): e111840, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25493630
9.
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Mol Cancer Ther
; 13(4): 842-54, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24563539
10.
E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia model.
Am J Physiol Lung Cell Mol Physiol
; 289(2): L207-16, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15805136